Korean Journal of Bronchoesophagology (대한기관식도과학회지)
- Volume 10 Issue 2
- /
- Pages.35-42
- /
- 2004
- /
- 1226-0916(pISSN)
Clinical Study for Efficacy and Safety of Rabeprazole Sodium(Pariet) in the Treatment of Laryngopharyngeal Reflex(LPR) Disease
인후두위산역류증(Laryngopharyngeal Reflux: LPR)의 치료에 대한 RabeprazoleSodium(Parietd)의 임상효과와 안전성 검토
- Jung, K.W. (Department of Otolaryngology, Korea Univ.,) ;
- Jun, B.S. (Department of Otolaryngology, Korea Univ.,) ;
- Ko, S.H. (Gachon Med. School) ;
- Kwon, K.H. (Sung Kyun Kwan Univ.) ;
-
Kwon, S.Y.
(Korea Univ.,) ;
- Kwon, J.K. (Ulsan Univ.,) ;
- Kim,, D.Y. (Gachon Med. School) ;
- Kim,, S.C. (Inje Univ.,) ;
- Kim,, S.W. (Kyung-Hee Univ.,) ;
- Kim,, Y.M. (Inha Univ.,) ;
- Kim,, Y.H. (Yonsei Univ.,) ;
- Kim,, Y.H. (Catholic Univ.,) ;
- Kim,, J.M. (Soonchunhyang Univ.,)
- 정광윤 (고려대학교 의과대학 이비인후과학교실) ;
- 전병선 (고려대학교 의과대학 이비인후과학교실) ;
- 고상현 (가천의대) ;
- 권기환 (성균관의대) ;
-
권순영
(고려의대) ;
- 권중근 (울산의대) ;
- 김동영 (가천의대) ;
- 김상철 (인제의대) ;
- 김성완 (경희의대) ;
- 김영모 (인하의대) ;
- 김영호 (연세의대) ;
- 김윤환 (가톨릭의대) ;
- 김장묵 (순천향의대)
- Published : 2004.12.01
Abstract
Background and objective : Rabeprazole is a new generation proton pump inhibitor, which has a rapid onset after first dose, predictable efficacy in all patients regardless of CYP2C19 genotype status, and less nocturnal acid breakthrough. The aim of the study is to investigate clinical efficacy and safety of rabeprazole sodium (Pariet 10mg qd)when administered once daily to patients with laryngopharyngeal reflux(LPR) disease. Methods : Among the patients who had visited the Department of Otolaryngology, those with LPR symptoms, had undergone laryngoscopy. Symptoms and endoscopic laryngeal sings were recorded initially, at 1 month, 2 months, 3 months, and more than 3 months, All patients were evaluated for clinical efficacy on the basis of symptom scores, reflux finding score(RFS), and side effects. Results : In general, most symptom scores and RFS improved over the time. Efficacy of the Pariet on LPR-related symptoms were